lornoxicam and Jaw-Diseases

68 patients in the age of 32-83 years (middle age 61.83 +/- 14.73 year) with the diagnosis acute odontogenic periostitis of jaw before treatment (at height of acuteness) and on a background of the complex treatment which include Xefocam were examined. It is shown, that treatment with addition of Xefocam accelerates regress of an inflammation and a stage of recovery. High analgetic activity of Xefocam at this pathology was revealed. The greatest efficiency of this drug is marked in group of patients of elderly and senile age. The opportunity of definition the Melatonin concentration in a saliva as marker of speed of inflammatory process regress is shown. The high level of Melatonin concentration in a saliva at peak of an inflammation is significant prognostic criterion of outcome of disease. The high level of Melatonin in saliva at the patients of advanced age who has survived in the childhood the siege of Leningrad in comparison with patients of similar age, who was not exposed in the childhood by multifactor stress impact influence, is revealed more.

Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Humans; Jaw Diseases; Melatonin; Middle Aged; Periostitis; Piroxicam; Saliva